Anti–PD-1 immunotherapy has demonstrated significant antitumor efficacy in relapsed or refractory NK/T-cell lymphoma (R/R NKTL), but resistance remains a substantial challenge. In this study, we evaluate DNA methyltransferase (DNMT) inhibitors combined with anti–PD-1 mAb in 21 patients with R/R NKTL for whom prior immunotherapy failed. This combination therapy achieved an objective response rate of 66.7% (14/21), with a complete response rate of 47.6% (10/21) and a 2-year overall survival rate of 50.2%. Preclinical models revealed that anti–PD-1 resistance was linked to the absence of CD8+ T-cell infiltration and suppressed IFN pathways. DNMT inhibitors reversed these effects, restoring CD8+ T-cell activities and tumor sensitivity to PD-1 blockade. Mechanistically, DNMT inhibitors triggered DNA demethylation of endogenous retroviral elements, activating viral mimicry via upregulated endogenous nucleic acids and type I IFN signaling. These findings underscore DNMT inhibitors’ role in overcoming PD-1 resistance and support their combination with anti–PD-1 as a promising strategy for R/R NKTL. Significance: Resistance to anti–PD-1 immunotherapy remains a substantial challenge in R/R NKTL. In this study, we reported that combining DNMT inhibitors with anti–PD-1 mAb achieves a high complete response rate of 47.6% in immunotherapy-R/R NKTL patients. Mechanistically, DNMT inhibitors potentiate anti–PD-1 efficacy by triggering viral mimicry, remodeling the immune microenvironment and augmenting antitumor immunity.
The aim of this study was to investigate the prognostic value of baseline PET/CT parameters alone and combined with clinical features in Extranodal Natural killer/T-cell lymphoma (ENKTL) patients treated with P-GEMOX regimen (pegaspargase, gemcitabine and oxaliplatin). A total of 97 patients were retrospectively evaluated. The relationships between baseline PETCT metabolic parameters and survival were tested using Cox regression analysis and receiver operating characteristic(ROC) curve analysis was employed to evaluate the optimal cut-off value of these parameters. Kaplan–Meier curves with log-rank tests were used for survival analysis. At a median follow-up of 49 months, the 3-year PFS and OS were 62.9% and 70.1%. SUVmean, SUVmax, and SUVpeak were related to both PFS and OS in univariate analysis(P < 0.05 for all). Further multivariate analysis including PET/CT parameters and clinical parameters revealed that SUVmean was an independent prognostic factor and seemed to be slightly superior to SUVmax and SUVpeak. The low SUVmean was significantly associated with a better prognosis (3-year OS 85.1% vs.65.0%, P = 0.014; 3-year PFS 76.8% vs.62.1%, P = 0.032). SUVmean was able to further separate patients with a low-risk PINK/PINKE of < 2(n = 85, 79, separately) into two subgroups with significantly different outcomes. Moreover, the metabolic-parameter-contained m-PINK/PINKE model was constructed and showed superior predictive performance in the whole cohort. Conclusions. SUVmean was an independent prognostic factor in patients with ENKTL treated with P-GEMOX chemotherapy. Adding SUVmean to the PINK or PINKE model could improve the predictive value and further distinguish patients with poor outcomes.
Anti–PD-1 immunotherapy has demonstrated significant antitumor efficacy in relapsed or refractory NK/T-cell lymphoma (R/R NKTL), but resistance remains a substantial challenge. In this study, we evaluate DNA methyltransferase (DNMT) inhibitors combined with anti–PD-1 mAb in 21 patients with R/R NKTL for whom prior immunotherapy failed. This combination therapy achieved an objective response rate of 66.7% (14/21), with a complete response rate of 47.6% (10/21) and a 2-year overall survival rate of 50.2%. Preclinical models revealed that anti–PD-1 resistance was linked to the absence of CD8+ T-cell infiltration and suppressed IFN pathways. DNMT inhibitors reversed these effects, restoring CD8+ T-cell activities and tumor sensitivity to PD-1 blockade. Mechanistically, DNMT inhibitors triggered DNA demethylation of endogenous retroviral elements, activating viral mimicry via upregulated endogenous nucleic acids and type I IFN signaling. These findings underscore DNMT inhibitors’ role in overcoming PD-1 resistance and support their combination with anti–PD-1 as a promising strategy for R/R NKTL.Significance:Resistance to anti–PD-1 immunotherapy remains a substantial challenge in R/R NKTL. In this study, we reported that combining DNMT inhibitors with anti–PD-1 mAb achieves a high complete response rate of 47.6% in immunotherapy-R/R NKTL patients. Mechanistically, DNMT inhibitors potentiate anti–PD-1 efficacy by triggering viral mimicry, remodeling the immune microenvironment and augmenting antitumor immunity.
Supplementary Figure S1. Tumor-infiltrating CD8+ cell was positive correlation to efficacy of the combined DNMT inhibition and anti-PD-1 mAb therapy. Supplementary Figure S2. No significant reduction in body weight of EL4 tumor-bearing mice with anti-PD-1 treatment. Supplementary Figure S3. Gating strategies for Figure 2D-F. Supplementary Figure S4. PD-L1 and PD-1 expression in pre-clinical models. Supplementary Figure S5. Immune related pathways were downregulated in EL4 P3 tumor. Supplementary Figure S6. No significant reduction in body weight of EL4 P3 tumor-bearing mice under different treatment. Supplementary Figure S7. DNMT inhibitors enhance CD8+ T cell activated and cytotoxicity in vivo. Supplementary Figure S8. DNMT inhibitors treatment did not affect PD-L1 expression in pre-clinical models. Supplementary Figure S9. DNMT inhibitors induce MHC-I and ISGs expression in EL4 cells. Supplementary Figure S10. IFNAR1 blockade attenuated the antitumor immunity induced by the combination of DAC and α-PD-1. Supplementary Figure S11. STING knockdown did not impair DNMT inhibitors induced CD8+ T cells activity. Supplementary Figure S12. DNMT inhibitors induces ERVs expression in human NKTL cells.